Skip to main content
logo
Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

COAG Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
Dec '25 Dec '24
Net Income
-63.91-48.71
Depreciation & Amortization
0.30.25
Share-Based Compensation
2.011.91
Other Operating Activities
0.120.96
Operating Cash Flow
-61.48-45.59
Capital Expenditures
-0.02-0.28
Change in Investments
-81.4762.19
Investing Cash Flow
-81.4861.9
Share Issuance / Repurchase
156.42-
Debt Issued / Paid
-0.12-0.1
Financing Cash Flow
156.3-0.1
Net Cash Flow
13.5716.21
Free Cash Flow
-61.49-45.87
Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).